🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationHow I verify my compounded peptide — consumer's testing guide

How I verify my compounded peptide — consumer's testing guide

PurityPaulOR Sun, May 31, 2026 at 4:44 PM 10 replies 423 viewsPage 1 of 2
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
May 31, 2026 at 4:44 PM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

The question I want answered is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. Tell me what I have not thought of.

— PurityPaulOR · corrections welcome and will be edited into this post with credit
48 18Dr.LeslieOBGYN, MikeNYC_runner and 45 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
May 31, 2026 at 4:50 PM#2
PurityPaulOR said:
They are two different exemptions from the same federal requirements and they buy different things.

PurityPaulOR has the substance of this right. The condition it depends on is worth stating. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

47 17MariaRD, AussieAnna, BethLabQueen and 44 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
May 31, 2026 at 4:56 PM#3
PurityPaulOR said:
They are two different exemptions from the same federal requirements and they buy different things.

Pushing back on PurityPaulOR here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

46 16tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 43 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
May 31, 2026 at 5:02 PM#4

Short answer first, then the reasoning. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: May 31, 2026 at 10:02 PM
45 15SkepticalSean, Dr.CardioMD, EndoResFellow and 42 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
May 31, 2026 at 5:30 PM#5
anders_CPH said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Second this.

44 14quinn_sf, NurseLeah_Nash, gary_naperville and 41 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register